Wijnans, L.

vaccine children pandemic study fluenza safety event adjuvanted report vaccination fluenza vaccine fi rst dose fluenza vaccines adolescent reaction 7.5 fever –17 group h 1n vaccine identi fied 6 months month guillain –barr syndrome age groups number reactogenicity immunogenicity surveillance 1.9 monovalent monitoring person identi split system transplant h 1n vaccination virion cell culture 03 adjuvanted vaccine 59-adjuvanted european ≥38.0 wijnan antigen attenuated immunization difference health virion 3.75 7559–7571 liang table amount trial country patient result vaccinated 03-adjuvanted control vaccine safety data pandemrix fluenza vaccination 1.9 ␮ g fi rst 03 adjuvanted syndrome –11 population publication overview association march narcolepsy disease trivalent formulation –23